Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.18 USD
−10.54 M USD
0.00 USD
6.85 M
About Intensity Therapeutics, Inc.
Sector
Industry
CEO
Lewis H. Bender
Website
Headquarters
Shelton
Founded
2012
FIGI
BBG00B57FZV6
Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of INTS is 2.79 USD — it has increased by 3.62% in the past 24 hours. Watch Intensity Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Intensity Therapeutics, Inc. stocks are traded under the ticker INTS.
INTS stock has fallen by −7.08% compared to the previous week, the month change is a −13.16% fall, over the last year Intensity Therapeutics, Inc. has showed a 22.39% increase.
We've gathered analysts' opinions on Intensity Therapeutics, Inc. future price: according to them, INTS price has a max estimate of 16.00 USD and a min estimate of 5.00 USD. Watch INTS chart and read a more detailed Intensity Therapeutics, Inc. stock forecast: see what analysts think of Intensity Therapeutics, Inc. and suggest that you do with its stocks.
INTS reached its all-time high on Dec 8, 2023 with the price of 11.44 USD, and its all-time low was 2.01 USD and was reached on Nov 17, 2023. View more price dynamics on INTS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INTS stock is 3.77% volatile and has beta coefficient of 0.93. Track Intensity Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Intensity Therapeutics, Inc. there?
Yes, you can track Intensity Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Intensity Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
INTS earnings for the last quarter are −0.25 USD per share, whereas the estimation was −0.30 USD resulting in a 18.03% surprise. The estimated earnings for the next quarter are −0.23 USD per share. See more details about Intensity Therapeutics, Inc. earnings.
Intensity Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
INTS net income for the last quarter is −3.51 M USD, while the quarter before that showed −4.97 M USD of net income which accounts for 29.33% change. Track more Intensity Therapeutics, Inc. financial stats to get the full picture.
No, INTS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 29, 2024, the company has 17.00 employees. See our rating of the largest employees — is Intensity Therapeutics, Inc. on this list?
Like other stocks, INTS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Intensity Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Intensity Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Intensity Therapeutics, Inc. stock shows the sell signal. See more of Intensity Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.